Sofinnova Investments
Sofinnova Investments, Inc. is a venture capital firm founded in 1974 and headquartered in Menlo Park, California, with additional offices in La Jolla, California, Montreal, Quebec, and Tokyo, Japan. The firm specializes in seed, early, and mid-stage investments, primarily focusing on the life sciences and information technology sectors. In life sciences, it targets clinical-stage pharmaceutical companies, biotechnology, and medical technologies addressing unmet medical needs, emphasizing areas such as oncology, neurology, and women’s health. For information technology, Sofinnova seeks product-oriented companies developing innovative software solutions and telecommunications infrastructure. The firm typically invests between $3 million and $15 million in technology companies and between $5 million and $30 million in life science companies, often requiring a board seat as part of its investment strategy. Sofinnova Investments emphasizes partnerships with entrepreneurs to help them build successful businesses and navigate key growth milestones, leveraging the expertise of its seasoned professionals.
Axonis Therapeutics
Series A in 2024
Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.